CS MEDICA A/S: CS MEDICA reports the results from the clinical trial on NGA-01(CANNASEN®CBD Arthritis Gel) against placebo
CS MEDICA (”CS MEDICA” or the ”Company”) announces today that the final efficacy analysis in their clinical trial of CANNASEN®CBD Arthritis Gel (NGA-01) met all the trial’s primary efficacy endpoints. Analysis of the data indicates that CANNASEN®CBD Arthritis Gel (NGA-01) has efficacy in reducing pain in joints, swelling, stiffness, and pain during flexion of joints of participants with osteoarthritis with joint pain in the joints; knee, hip, ankle, elbow and shoulder. The final objective analysis is based on 60 cases of osteoarthritis, as specified in the study protocol.The trial data show